These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 30359679)

  • 1. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
    Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
    J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
    Lacout M; Guinet-Lacoste A; Popoff M; Verollet D; Lebreton F; Amarenco G
    Prog Urol; 2015 Sep; 25(11):642-8. PubMed ID: 26094097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.
    Mailho C; Peyronnet B; De Seze M; Even A; Perrouin-Verbe MA; Amarenco G; Chartier-Kastler E; Le Normand L; Manunta A; Karsenty G; Kerdraon J; Ruffion A; Saussine C; Le Breton F; Bernuz B; Castel-Lacanal E; Denys P; Phé V; Gamé X
    Neurourol Urodyn; 2024 Apr; 43(4):811-817. PubMed ID: 38451038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Marque P; Rischmann P; Gamé X
    World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
    Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
    Kaviani A; Khavari R
    Urol Clin North Am; 2017 Aug; 44(3):463-474. PubMed ID: 28716326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury.
    Hebert KP; Klarskov N; Bagi P; Biering-Sørensen F; Elmelund M
    Spinal Cord; 2020 Jun; 58(6):675-681. PubMed ID: 31913344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity.
    Joussain C; Popoff M; Phé V; Even A; Bosset PO; Pottier S; Falcou L; Levy J; Vaugier I; Chartier Kastler E; Schurch B; Denys P
    Neurourol Urodyn; 2018 Feb; 37(2):799-806. PubMed ID: 28745807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections].
    Karsenty G; Corcos J; Schurch B; Ruffion A; Chartier-Kastler E
    Prog Urol; 2007 May; 17(3):568-75. PubMed ID: 17622092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.